Efficacy of Peptide Receptor Radionuclide Therapy for Functional Metastatic Paraganglioma and Pheochromocytoma

@article{Kong2017EfficacyOP,
  title={Efficacy of Peptide Receptor Radionuclide Therapy for Functional Metastatic Paraganglioma and Pheochromocytoma},
  author={G. Kong and S. Grozinsky-Glasberg and M. Hofman and J. Callahan and A. Meirovitz and Ofra Maimon and D. Pattison and D. Gross and R. Hicks},
  journal={The Journal of Clinical Endocrinology & Metabolism},
  year={2017},
  volume={102},
  pages={3278–3287}
}
  • G. Kong, S. Grozinsky-Glasberg, +6 authors R. Hicks
  • Published 2017
  • Medicine
  • The Journal of Clinical Endocrinology & Metabolism
  • Purpose: Treatment options for unresectable paraganglioma (PGL)/pheochromocytoma (PCC), especially with uncontrolled secondary hypertension (HTN), are limited. Preliminary studies with peptide receptor radionuclide therapy (PRRT) suggest efficacy, but data on HTN control and survival are lacking. We assessed PRRT outcomes in such patients from two referral centers. Methods: Twenty consecutive patients (13 men; age range, 21 to 77 years) with high somatostatin receptor (SSTR) expression treated… CONTINUE READING
    55 Citations
    Metastatic pheochromocytoma and paraganglioma: recent advances in prognosis and management
    • Oksana Hamidi
    • Medicine
    • Current opinion in endocrinology, diabetes, and obesity
    • 2019
    • 7
    Concomitant 177Lu-DOTATATE and capecitabine therapy in malignant paragangliomas
    • 13
    • Highly Influenced
    Symptomatic and Radiological Response to 177Lu-DOTATATE for the Treatment of Functioning Pancreatic Neuroendocrine Tumors
    • 19
    • PDF

    References

    SHOWING 1-10 OF 33 REFERENCES
    Peptide receptor radionuclide therapy for metastatic paragangliomas
    • 18
    Treatment with sunitinib for patients with progressive metastatic pheochromocytomas and sympathetic paragangliomas.
    • 134
    • PDF
    Radiolabeled DOTATOC in patients with advanced paraganglioma and pheochromocytoma.
    • F. Forrer, I. Riedweg, H. Mäcke, J. Mueller-Brand
    • Medicine
    • The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of...
    • 2008
    • 93
    Survival of patients with metastatic malignant pheochromocytoma and efficacy of combined cyclophosphamide, vincristine, and dacarbazine chemotherapy.
    • 58
    • PDF
    Peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE in individuals with neck or mediastinal paraganglioma (PGL).
    • 57
    Phase 3 Trial of 177Lu‐Dotatate for Midgut Neuroendocrine Tumors
    • 928
    • PDF
    Phase II study of high-dose [131I]metaiodobenzylguanidine therapy for patients with metastatic pheochromocytoma and paraganglioma.
    • 145